Peptide LibraryPNC-27
Also known as: p53-MDM2 peptide, PNC27
PNC-27 (also called p53-MDM2 peptide or PNC27) is an experimental anticancer peptide in the Membrane-lytic research peptide class. PNC-27 is a synthetic peptide joining a p53 -derived HDM-2 binding region to a membrane-penetrating leader sequence.
For research use only.
Key Facts
- CAS
- 1159861-00-3
- Molecular Weight (MW)
- 4032 g/mol
- Half-life
- —
- FDA status
- Not Approved
- Evidence level
- Insufficient Evidence
- Human dose established
- No
- Administration Route
- Not established in humans
- Frequency
- Not established in humans
- Last updated
- Nov 7, 2026
- Reviewed
- Nov 7, 2026
- Targets
- Membrane HDM-2 (claimed)
Vendor price snapshot
Each vendor counts once, at the median price per mg of its own listings; the typical range is the middle half of vendors. From public vendor listings collected between Oct 2026 and Nov 2026, so confirm the live price on the vendor site. Peptide Library does not sell peptides.
- Vendors listing this peptide
- 6
- Listed offers
- 10
- Median price per mg (peptide vials)
- $10.45/mg
- Typical $10.45–$16.24/mg
By form
Each form is priced on its own: a price per mg doesn't make a spray or a capsule equivalent to a vial.
- Peptide vials6 vendors · median $10.45/mg
- Sprays, route not stated1 vendor · $13.80/mg
Research summary
Experimental peptide containing a p53 motif designed to lyse cancer-cell membranes in preclinical papers. Not FDA-approved; not a cancer treatment.
Research evidence
- Regulatory review (FDA label)None in reviewed sources
- Controlled human trialsNone in reviewed sources
- Early or uncontrolled human studiesNone in reviewed sources
- Lab & animal studies2 reviewed sources
How it works
Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess.
Peptide Library's PNC-27 profile summarises 5 cited studies listed in the Science section, the compound's regulatory status, and research-protocol parameters reported for it. It is a research reference, not medical advice.
PNC-27 dosage: no established human dose
PNC-27 has no established human dosage. No trial of it is registered on ClinicalTrials.gov and no human study is indexed in PubMed. The published work is in cancer cell lines and in mice carrying transplanted human tumours, where cell-culture work is reported as a concentration in the dish rather than a dose given to a person.
No established human dosage.
Human clinical evidence: None identified.
Preclinical research: PNC-27 is a synthetic peptide joining a segment of the p53 protein to a cell-penetrating sequence. It binds HDM-2 in the membrane of cancer cells and opens pores in it, which the authors call poptosis. All published work is in cell culture and in mice with transplanted tumours. Cell-culture figures are concentrations in the medium, and mouse work is injected into the abdominal cavity, so neither gives a human dose, route or interval.
Animal dosing is not converted into a human dose anywhere on this page. Where research figures appear below, they are reported as studied, not recommended.
| Human dosing established | No |
|---|---|
| Route | Not established in humans |
| Evidence level | Insufficient Evidence |
| Last reviewed | 2026-11-07 |
Preclinical and analog research
Not human dosing evidence. Listed for completeness and never extrapolated to a human dose.
| Study / context | Population | Dose | Route | Frequency | Duration | Outcome studied | Source |
|---|---|---|---|---|---|---|---|
| Preclinical — PNC-27 in cervical cancer and normal cervical cell lines (2025)Preclinical · Cell-culture study | Human cell lines: HTB-35 (SiHa) cervical cancer cells and untransformed PCS-480 cervical cells | IC50 12.4 micromolar in the culture medium (laboratory concentration, not a dose given to a person) | In vitro | — | — | Killed the cancer cell line but not the untransformed cell line; the authors link this to HDM-2 in the cancer cell membrane | HDM-2-Targeting Peptide PNC-27 Kills Cervical Cancer Cells but not Normal Cervical Cells. Ann Clin Lab Sci. 2025. |
| Preclinical — PNC-27 in human and mouse acute myeloid leukaemia models (2020)Preclinical · Animal and cell study | Mice carrying human and murine AML, including leukaemia stem cell-enriched populations; transplant experiments in wild-type mice | Not stated in the indexed abstract | Not stated in the indexed abstract | — | — | Killed AML blasts and leukaemia stem cells in the models while sparing normal haematopoietic stem cell activity | Targeting cell membrane HDM2: A novel therapeutic approach for acute myeloid leukemia. Leukemia. 2020. |
| Preclinical — PNC-28, a shorter related peptide, in pancreatic tumour-bearing mice (2006)Preclinical · Animal study of a related peptide (analog evidence)Studied an analog, not PNC-27 itself | Nude mice with transplanted BMRPA1.Tuc3 pancreatic carcinoma cells | Not stated in the indexed abstract | Intraperitoneal | — | 2 weeks of administration | Destruction of the transplanted tumours; tumour growth resumed slowly after treatment stopped | PNC-28, a p53-derived peptide that is cytotoxic to cancer cells, blocks pancreatic cancer cell growth in vivo. Int J Cancer. 2006. |
Where sources disagree
- PNC-27 and PNC-28 are different peptides. Mouse results obtained with PNC-28 are listed here as related-peptide evidence and are not evidence of a dose of PNC-27.
- A concentration that kills cells in a dish (for example a micromolar IC50) is not a dose. It cannot be converted into an amount for a person.
- Several of the publications involve companies holding a commercial interest in these peptides, which the papers disclose.
Reconstitution
Common research vial sizes: 10 mg.
| Vial | Bacteriostatic water | Concentration | Per 0.01 mL |
|---|---|---|---|
| 10 mg | 2 mL | 5 mg/mL | 50 mcg per 0.01 mL |
These figures are arithmetic only — they convert a vial and a volume into a concentration. They are not a recommendation to take any dose.
Calculate reconstitution & dose →Handling & administration
- Injection Sites
- AbdomenThigh
- Timing Notes
- Educational catalog only — not medical advice
Sequence & molecular data
| Molecular formula | C188H293N53O44S |
|---|---|
| Molecular weight | 4032 g/mol |
| CAS number | 1159861-00-3 |
| Appearance | White lyophilized powder |
| Formulation | Lyophilized Powder |
| PubChem CID | 16201774 |
Identifiers link to the public PubChem, FDA Substance Registration (UNII), ChEMBL and DrugBank records for the same entity.
Science
Mechanism of Action
PNC-27 is a synthetic peptide joining a p53 -derived HDM-2 binding region to a membrane-penetrating leader sequence. The proposed mechanism is that it binds HDM-2 present in the plasma membrane of cancer cells — reported to be expressed there in transformed but not normal cells — and forms transmembrane pores, causing rapid necrotic lysis rather than apoptosis. Selectivity in this model derives entirely from the claimed differential membrane localisation of HDM-2. The evidence is preclinical and comes largely from a small number of groups, replication is limited, and there are no clinical trials. Products sold under this name are research chemicals, not oncology drugs.
Origin
Synthetic p53-derived peptide.
Targets
Studies
- HDM-2-Targeting Peptide PNC-27 Kills Cervical Cancer Cells but not Normal Cervical Cells
- Anti-Cancer Peptide PNC-27 Kills Cancer Cells by Unique Interactions with Plasma Membrane-Bound hdm-2 and with Mitochondrial Membranes Causing Mitochondrial Disruption
- Conjugated PNC-27 peptide/PEI-superparamagnetic iron oxide nanoparticles (SPIONs) as a double targeting agent for early cancer diagnosis: In vitro study
- PNC-27, a Chimeric p53-Penetratin Peptide Binds to HDM-2 in a p53 Peptide-like Structure, Induces Selective Membrane-Pore Formation and Leads to Cancer Cell Lysis
- Targeting Membrane HDM-2 by PNC-27 Induces Necrosis in Leukemia Cells But Not in Normal Hematopoietic Cells
Research statistics
23 PubMed publications · 4.3% human clinical research · 0 registered trials
Counts of published research through 2026-11-01, not evidence that it works. Publications by year, study types and trials · How publications are counted
Regulatory & research status
PNC-27 is not an FDA-approved product. It is sold for laboratory research and has no approved medical use.
| FDA status | Not Approved |
|---|---|
| Availability | Research-Only |
| WADA (sport) | Unknown / Not Listed |
| Library classification | Research-Only |
How FDA approval, compounding and research-only status differ
Benefits
PNC-27 side effects
PNC-27 has no controlled human safety data. The effects below are reported, not established, and absence from the list is not evidence of safety.
Side Effects
- Unknown; membrane-lytic peptides can be cytotoxic
Storage & stability
Lyophilized (freeze-dried) peptide powder is far more stable than the reconstituted solution. Keep sealed vials cold, dry and away from light; long-term storage is typically frozen, with short-term refrigeration for vials in use.
Once reconstituted in bacteriostatic water, keep the solution refrigerated, avoid repeated freeze–thaw cycles and agitation, and label the vial with the reconstitution date and concentration. Discard any solution that turns cloudy or shows particulates.
Degradation rates differ by sequence: peptides containing methionine, cysteine, asparagine or glutamine are more prone to oxidation and deamidation, so shelf life after reconstitution is compound-specific rather than universal.
Read the full guide: how to store peptides before and after reconstitution →
Source: Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544–575. (PMID 20143256). General guidance for research handling; not product-specific instructions.
PNC-27: frequently asked questions
What is PNC-27?
Experimental peptide containing a p53 motif designed to lyse cancer-cell membranes in preclinical papers. Not FDA-approved; not a cancer treatment.
How does PNC-27 work?
PNC-27 is a synthetic peptide joining a p53 -derived HDM-2 binding region to a membrane-penetrating leader sequence. The proposed mechanism is that it binds HDM-2 present in the plasma membrane of cancer cells — reported to be expressed there in transformed but not normal cells — and forms transmembrane pores, causing rapid necrotic lysis rather than apoptosis.
Is PNC-27 FDA approved?
No. PNC-27 is not approved by the FDA for any indication and is categorised as research-only. It has not been reviewed for safety or efficacy as a medicine, and published research should be read as investigation rather than established use.
What peptides are similar to PNC-27?
Compounds most often compared with PNC-27 include Bonomarlot, Bronchogen, Chonluten and Glutathione. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.
References
- HDM-2-Targeting Peptide PNC-27 Kills Cervical Cancer Cells but not Normal Cervical Cells — Ann Clin Lab Sci, 2025External reference
- Anti-Cancer Peptide PNC-27 Kills Cancer Cells by Unique Interactions with Plasma Membrane-Bound hdm-2 and with Mitochondrial Membranes Causing Mitochondrial Disruption — Ann Clin Lab Sci, 2024External reference
- Conjugated PNC-27 peptide/PEI-superparamagnetic iron oxide nanoparticles (SPIONs) as a double targeting agent for early cancer diagnosis: In vitro study — Iran J Basic Med Sci, 2022External reference
- PNC-27, a Chimeric p53-Penetratin Peptide Binds to HDM-2 in a p53 Peptide-like Structure, Induces Selective Membrane-Pore Formation and Leads to Cancer Cell Lysis — Biomedicines, 2022External reference
- Targeting Membrane HDM-2 by PNC-27 Induces Necrosis in Leukemia Cells But Not in Normal Hematopoietic Cells — Anticancer Res, 2020External reference
Related research, comparisons & guides
Related peptides
Compiled by Peptide Library Editorial · Reviewed Aug 30, 2026 · Updated Nov 7, 2026 · Version 3
This PNC-27 profile is compiled from published literature (5 cited studies linked above), public regulatory records and chemical registries. It describes what research reports; it is not medical advice, and nothing here is a dosing recommendation for humans. Peptide Library does not sell peptides. Editorial policy · How profiles are compiled · Report an error
Track PNC-27 research, inventory and reconstitution in the free Peptide Library app. Get the app for iOS or Android →